Internal hemipelvectomy

Until recently, tumours involving the pelvis were usually treated by hemipelvectomy, otherwise called 'hindquarter amputation'. A more recent approach of treating these tumours is the 'conservative hemipelvectomy', which consists of removing the tumour and sparing the lower extremity. A patient with Ewing's sarcoma of the pelvis underwent such a procedure. The femoral head was fixed temporarily to the remaining parts of the acetabulum and the iliac wing by a Steinman pin. The Steinman pin was removed 6 weeks after the operation and the patient was then put into traction for another 6 weeks. Weight-bearing was gradually allowed after 3 to 6 months. The patient remodelled a neoacetabulum, which gave sufficient stability to the hip joint. Walking without external help was possible. The patient presented with a 2 cm limb-shortening. No local recurrence was observed during a follow-up of 30 months. This experience with internal hemipelvectomy shows an encouraging result in terms of tumour control and gait function.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Neoadjuvant chemotherapy with cisplatin, methotrexate, bleomycin and vincristine (CABO) in patients with Stage III and IV squamous cell carcinoma of the head and neck

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A phase II study of cisplatin (CDDP) and epirubicin (EPI) in malignant pleural mesothelioma (MPM)

ECCO 12, Copenhagen, 21-25/09/03 A study by the European Lung Cancer Working Party (ELCWP).info:eu-repo/semantics/publishedsuppl.

Randomised study of concomitant radiochemotherapy (RT-CT) in patients with locally advanced unresectable non-small cell lung cancer (NSCLC): interim toxicity analysis

29th ESMO Congress, Vienna, Austria, 2004 A study by the European Lung Cancer Working Party (ELCWP)info:eu-repo/semantics/publishedsuppl 3 :iii172 (649P

Concurrent radiochemotherapy (RT-CT) with cisplatin (C), gemcitabine (G) and vinorelbine (V) in patients with locally advanced non-small cell lung cancer (NSCLC): preliminary toxicity results within a randomized trial of European Lung Cancer Working Party (ELCWP)

9th Central European Lung Cancer Conference, Gdansk, Poland, 23-25/09/2004info:eu-repo/semantics/publishedsuppl

A feasibility study preparing to a phase III randomised trial comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. A trial conducted by the European Lung Cancer Working Party (ELCWP)

11th World Conference on Lung cancer, Barcelona, Spaininfo:eu-repo/semantics/publishedsuppl 2, P-19

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

The purpose of this study was to determine the activity of paclitaxel as a second-line chemotherapy for non-small cell lung cancer (NSCLC). This multicentric trial included patients who had failed to a first-line chemotherapy with platinum derivatives and/or ifosfamide. After registration, patients were treated by paclitaxel i.v. at a dose of 225 mg/m2 given over 3 h administered every 3 weeks. Response was assessed after three courses of therapy. Sixty-seven patients were registered, one was ineligible and 64 were assessable for response. Two partial responses were observed (3% of the eligible patients; 95% confidence interval: 0-7%). No change was documented in 16 cases (24%). Tolerance was acceptable, the main toxicity being cumulative polyneuropathy. Median survival duration was 4.5 months with a 1-year rate at 19%. We concluded that paclitaxel is not active in terms of response as second-line chemotherapy for NSCLC. © 2002 Elsevier Science Ireland Ltd. All rights reserved.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A phase II study testing weekly platinum derivative combination chemotherapy as second-line treatment in patients with advanced small cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A phase II study testing a combination chemotherapy with epirubicin and vindesine as second line treatment for patients with advanced non-small cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe